Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Effect on Endothelial Function in Patients with Rheumatoid Arthritis
2011-000215-79Phase 3Terminated
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Flow-mediated dilation of peripheral arteries. Started Feb 2011; status: terminated.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-000215-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000215-79.